Efficacy and Safety of Sotagliflozin by Baseline Renal Function in Adults with Type 1 Diabetes

被引：0
|
作者：
Handelsman, Yehuda
Giaccari, Andrea
Sawhney, Sangeeta
Banks, Phillip L.
Davies, Michael J.
Lapuerta, Pablo
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-1100-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1100-P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease
    Cherney, David Z. I.
    Ferrannini, Ele
    Umpierrez, Guillermo E.
    Peters, Anne L.
    Rosenstock, Julio
    Powell, David R.
    Davies, Michael J.
    Banks, Phillip
    Agarwal, Rajiv
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1646 - 1657
  • [22] Balancing the Risk of DKA and Severe Hypoglycemia with Sotagliflozin in Adults with Type 1 Diabetes
    Pettus, Jeremy
    Cariou, Bertrand
    Sawhney, Sangeeta
    Banks, Phillip L.
    Davies, Michael J.
    Lapuerta, Pablo
    DIABETES, 2020, 69
  • [23] A review of sotagliflozin for use in type 1 diabetes
    Nuffer, Wesley
    Williams, Briana
    Trujillo, Jennifer M.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2019, 10
  • [24] ICE guidance on sotagliflozin for type 1 diabetes
    Adler, Amanda I.
    Cronshaw, Jessica
    Prescott, Carl
    Patel, Sanjeev
    Donegan, Eleanor
    Hayre, Jasdeep
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (04): : 274 - 275
  • [25] Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials
    Musso, Giovanni
    Gambino, Roberto
    Cassader, Maurizio
    Paschetta, Elena
    BMJ-BRITISH MEDICAL JOURNAL, 2019, 365
  • [26] Efficacy and safety of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct to insulin in young adults with poorly controlled type 1 diabetes (JDRF Study)
    Bode, B.
    Banks, P.
    Sawhney, S.
    Strumph, P.
    DIABETOLOGIA, 2017, 60 : S87 - S88
  • [27] Efficacy and safety of sotagliflozin in patients with type 2 diabetes: meta-analysis of randomised controlled trials
    Kakotrichi, P.
    Avgerinos, I.
    Karagiannis, T.
    Michailidis, T.
    Liakos, A.
    Tsapas, A.
    Bekiari, E.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 256 - 257
  • [28] Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes with a High Baseline A1c
    Skolnik, Neil
    Bonnes, Harmony
    Katz, Arie
    Yeh, Helen
    DIABETES, 2015, 64 : A653 - A653
  • [29] Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study
    Bode, Bruce W.
    Cengiz, Eda
    Wadwa, R. Paul
    Banks, Phillip
    Danne, Thomas
    Kushner, Jake A.
    McGuire, Darren K.
    Peters, Anne L.
    Strumph, Paul
    Sawhney, Sangeeta
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (01) : 59 - 69
  • [30] Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes
    Khoo, Teck K.
    Olson, Kristin M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (10): : 967 - 967
12345